Stryker Co. (NYSE:SYK) Stake Boosted by Beese Fulmer Investment Management Inc.

Beese Fulmer Investment Management Inc. increased its position in shares of Stryker Co. (NYSE:SYK) by 0.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,417 shares of the medical technology company’s stock after acquiring an additional 224 shares during the period. Stryker comprises approximately 1.3% of Beese Fulmer Investment Management Inc.’s portfolio, making the stock its 22nd biggest holding. Beese Fulmer Investment Management Inc.’s holdings in Stryker were worth $15,272,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Dynamic Advisor Solutions LLC increased its holdings in Stryker by 2.3% in the third quarter. Dynamic Advisor Solutions LLC now owns 2,990 shares of the medical technology company’s stock worth $1,080,000 after buying an additional 67 shares during the last quarter. Atomi Financial Group Inc. increased its stake in shares of Stryker by 2.3% during the 3rd quarter. Atomi Financial Group Inc. now owns 2,091 shares of the medical technology company’s stock worth $755,000 after purchasing an additional 47 shares during the last quarter. Abner Herrman & Brock LLC raised its holdings in shares of Stryker by 0.3% during the 3rd quarter. Abner Herrman & Brock LLC now owns 31,405 shares of the medical technology company’s stock valued at $11,345,000 after purchasing an additional 106 shares in the last quarter. Wedmont Private Capital lifted its stake in shares of Stryker by 3.9% in the 3rd quarter. Wedmont Private Capital now owns 3,414 shares of the medical technology company’s stock valued at $1,178,000 after purchasing an additional 127 shares during the last quarter. Finally, Steigerwald Gordon & Koch Inc. boosted its holdings in Stryker by 1.6% in the third quarter. Steigerwald Gordon & Koch Inc. now owns 70,235 shares of the medical technology company’s stock worth $25,373,000 after purchasing an additional 1,115 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on SYK. BTIG Research boosted their price target on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Truist Financial boosted their target price on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a report on Thursday, January 30th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $370.00 to $445.00 in a report on Monday, December 2nd. UBS Group boosted their price objective on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Finally, JPMorgan Chase & Co. raised their target price on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $419.37.

Insider Activity

In other news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 5.50% of the company’s stock.

Stryker Stock Performance

SYK opened at $396.24 on Friday. The stock has a market cap of $151.06 billion, a PE ratio of 51.06, a P/E/G ratio of 2.78 and a beta of 0.96. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The stock’s 50 day simple moving average is $377.08 and its 200-day simple moving average is $364.24. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the previous year, the business posted $3.46 earnings per share. Sell-side analysts forecast that Stryker Co. will post 13.5 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.85%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.